AVADEL PHARMACEUTICALS PLC's ticker is AVDL and the CUSIP is 05337M104. A total of 101 filers reported holding AVADEL PHARMACEUTICALS PLC in Q3 2023. The put-call ratio across all filers is 0.37 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $469,536 | -37.5% | 45,586 | 0.0% | 0.10% | +35.7% |
| Q2 2023 | $751,257 | +929.1% | 45,586 | +52.0% | 0.07% | +1066.7% |
| Q2 2022 | $73,000 | -91.6% | 30,000 | -72.2% | 0.01% | -88.7% |
| Q4 2021 | $873,000 | +52.4% | 108,079 | +84.7% | 0.05% | +211.8% |
| Q3 2021 | $573,000 | -63.2% | 58,501 | -74.7% | 0.02% | -37.0% |
| Q2 2021 | $1,555,000 | -29.5% | 231,073 | -5.3% | 0.03% | -28.9% |
| Q1 2021 | $2,206,000 | -4.5% | 244,068 | -29.4% | 0.04% | -9.5% |
| Q4 2020 | $2,310,000 | +188.0% | 345,767 | +117.2% | 0.04% | +133.3% |
| Q3 2020 | $802,000 | -37.6% | 159,200 | 0.0% | 0.02% | -35.7% |
| Q2 2020 | $1,286,000 | -42.2% | 159,200 | -43.2% | 0.03% | -49.1% |
| Q1 2020 | $2,224,000 | -5.1% | 280,200 | -9.7% | 0.06% | +44.7% |
| Q4 2019 | $2,344,000 | – | 310,469 | – | 0.04% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| WEALTH EFFECTS LLC | 2,305,017 | $18,625,000 | 7.73% |
| COWEN AND COMPANY, LLC | 3,732,778 | $30,161,000 | 2.74% |
| GENDELL JEFFREY L | 2,446,299 | $19,766,000 | 1.60% |
| Asymmetry Capital Management, L.P. | 369,134 | $2,983,000 | 1.58% |
| Vivo Capital, LLC | 2,937,093 | $23,732,000 | 1.43% |
| Samsara BioCapital, LLC | 659,409 | $5,328,000 | 1.03% |
| Altium Capital Management LP | 440,589 | $3,560,000 | 0.98% |
| Knott David M Jr | 258,198 | $2,086,000 | 0.71% |
| RTW INVESTMENTS, LP | 5,741,939 | $46,395,000 | 0.68% |
| FRAZIER MANAGEMENT LLC | 951,814 | $7,691,000 | 0.59% |